The vibrant, dynamic performances at the Harvard for Haiti concert on Feb. 12 made for a stark contrast with the reality of the Jan. 12 earthquake disaster in Haiti. But Harvard College students raised almost $37,000 at their sold-out benefit show at Sanders Theatre.The production was wholly underwritten by Harvard University, meaning all of the money raised will go to Partners In Health, a Harvard-affiliated nongovernmental organization that has been working in Haiti for more than 20 years.The concert, produced and performed by the students, featured performances that were varied in style but uniformly moving. Violinist Ryu Goto ’10 played with such passion that he frayed his bow.The Pan-African Dance and Music Ensemble got the audience moving and clapping along in their seats during a performance of “Drum Call.” Following a reflection by Harvard College Dean Evelynn Hammonds, the Kuumba Singers ended the evening with modern and traditional gospel songs about community and resilience.Sanders was filled to the rafters, as President Drew Faust noted in her welcoming remarks. But the audience extended far beyond the theater, as almost 3,500 watched live via Webcast. The online audience donated to the cause via the Harvard for Haiti Web site.After the concert, the Student Alliance for Global Health hosted a reception at the Queen’s Head Pub in Harvard Yard to help concertgoers learn more about the health implications of the disaster and what else they can do get involved. HHI, iPhone connection Michael VanRooyen, director of the Harvard Humanitarian Initiative, addressed the audience … also mentioning a special iPhone app that was used in the rescue effort. Magic in motion The Caribbean Club Dance Team performs “Simplement Danse,” choreographed by Akilah Crichlow ’10. Photos by Jon Chase/Harvard Staff Photographer Classic moment The Harvard for Haiti Benefit Concert at Sanders Theatre included student performers from across campus. Ryu Goto ’11 performs Paganiniana Variations for Solo Violin. Harvard for Haiti Benefit Concert Moore’s dance Merritt Moore ’10 performs a dance titled “A Day Without Rain” to the capacity crowd at Sanders Theatre. Piano man Charlie Albright ’11 performs two pieces during the benefit concert. Kuumba contribution The Harvard for Haiti Benefit Concert at Sanders Theatre included the Kuumba Singers of Harvard College. The University has established a relief fund for Harvard faculty and staff directly affected by the earthquake in Haiti. Donations can be made online, in person, or by mail through the Harvard Credit Union.
An artificial pancreas system that closely mimics the body’s blood sugar control mechanism was able to maintain near-normal glucose levels without causing hypoglycemia in a small group of patients.The system, combining a blood glucose monitor and insulin pump technology with software that directs administration of insulin and the blood-sugar-raising hormone glucagon, was developed at Boston University (BU).The first clinical trial of the system was conducted by Harvard researchers at Massachusetts General Hospital (MGH) and confirmed the feasibility of an approach utilizing doses of both hormones. In their report, appearing in Science Translational Medicine, the researchers also found unexpectedly large differences in insulin absorption rates between study participants, differences they were able to account for by adjustments to the system.“This is the first study to test an artificial pancreas using both insulin and glucagon in people with type 1 diabetes. It showed that, by delivering both hormones in response to frequent blood sugar tests, it is possible to control blood sugar levels without hypoglycemia, even after high-carbohydrate meals,” says Steven Russell, a Harvard Medical School (HMS) instructor in medicine in the MGH Diabetes Unit, who co-led the research team with Edward Damiano of the BU Department of Biomedical Engineering.In type 1 diabetes, the insulin-producing beta cells of the pancreas are destroyed by the immune system, requiring insulin treatment to regulate blood sugar levels. Intensive glucose control involving frequent blood sugar testing and insulin administration can delay or prevent long-term complications – such as retinal damage, kidney failure, or cardiovascular disease – but is extremely demanding and difficult to maintain. Continuous glucose monitors and insulin pumps can help, but patients remain at risk for hypoglycemia, a potentially life-threatening drop in blood sugar caused by too much insulin.Because any administration of insulin, even by an artificial pancreas system, has been associated with the risk of hypoglycemia, BU investigators Damiano and lead author Firas El-Khatib developed a system that both accounts for the rate of insulin absorption and also incorporates glucagon, a hormone naturally released by the pancreas to raise blood sugar levels. While the alpha cells of the pancreas that produce glucagon are not destroyed in people with type 1 diabetes, the cells no longer release glucagon in response to low blood sugar.“Large doses of glucagon are used as a rescue drug for people with severely low blood sugar,” explains Damiano. “Our system is designed to counteract moderate drops in blood sugar with minute doses of glucagon spread out throughout the day, just as the body does in people without diabetes.” In 2007 Damiano’s team tested the system in diabetic pigs, which led to FDA approval of the human trial.The current study enrolled 11 adults with type 1 diabetes and was primarily designed to test the software that controls the system. To get the most accurate glucose levels, the system used a monitor that directly reads blood sugar through a sensor placed into a vein instead of a continuous glucose monitor that takes readings under the skin.Participants’ blood sugar was controlled by the system for 27 hours, during which time they ate three standardized, high-carbohydrate meals and slept through the night at the hospital. While the system kept glucose levels close to the target range for six participants, five others experienced hypoglycemia significant enough that they needed a dose of orange juice to raise their blood sugar.Close analysis of participants’ blood-insulin levels revealed a nearly fourfold difference in the rate at which individuals absorbed and cleared the fast-acting insulin used in the study, with some rates of absorption being much slower than anticipated. Since the controlling software determined dosage based on the expected rate of insulin absorption, participants who absorbed at a slower rate received excessive doses, leading to hypoglycemia.A test of participants’ response to a single insulin injection verified that some had consistently slow and some consistently fast rates of insulin absorption. Rates of absorption also varied too much from experiment to experiment, even on an individual basis, to allow participant-specific dosage calculations.After globally adjusting the software parameters to a slower insulin absorption rate, the researchers conducted repeat experiments in the same participants. This time none of the slow-absorption participants experienced hypoglycemia significant enough to require intervention. Blood-sugar levels were only slightly higher in repeat experiments involving participants with fast insulin absorption, showing that the adjusted software parameters were effective for all study participants and may be adequate for everyone with type 1 diabetes.The elimination of episodes of hypoglycemia in repeat experiments involving the same participants affirmed that the initial mismatch between parameter settings and insulin absorption rate had been the cause of the hypoglycemia. All previous reported studies of artificial pancreas systems have included episodes of hypoglycemia, but this is the first study to confirm and address the cause of that hypoglycemia.Later this spring the researchers will begin a follow-up study with a system using the revised settings and driven by an FDA-approved continuous glucose monitor. Those experiments will last more than 48 hours and include children as well as adults. The investigators also plan to compare the insulin/glucagon system with a version that uses only insulin. “The device we ultimately envision will be wearable and incorporate a glucose sensor inserted under the skin that communicates wirelessly with a pump about the size of a cell phone,” says Harvard’s Russel. “The pump would administer insulin and probably glucagon, and would contain a microchip that runs the control software.”Damiano, whose 11-year-old son was diagnosed with type 1 diabetes at the age of 1, adds, “a system like this would replace the need for people to constantly check their blood sugar and to make treatment decisions every few hours. It would need to be maintained but could take over the decision-making process, closely emulating a functioning pancreas. It wouldn’t be a cure, but it has the potential to be the ultimate evolution of insulin therapy for type 1 diabetes.” Damiano is an associate professor of Biomedical Engineering at Boston University.The study was supported by grants from the Juvenile Diabetes Research Foundation, the Wallace H. Coulter Foundation, the Charlton Fund for Innovative Research in Diabetes and the National Center for Research Resources. Co-authors of the paper are David M. Nathan, MD, professor of medicine at HMS and director of the MGH Diabetes Center, and Robert Sutherlin, RN, also of the MGH Diabetes Center.
Share67Tweet15Share11Email93 SharesGiant Sequoia National Monument / David PrasadJuly 26th, 2017; Hawaii News NowPeople making sentimental appeals on behalf of environmental causes often say things like, “We have to preserve our natural treasures for our children.” One kid from Hawaii apparently didn’t think the grown-ups were doing a good enough job, so he stepped up to do it himself. Nine-year-old Robbie Bond founded a nonprofit called Kids Speak for Parks, and kicked off his summer-long tour of America’s greatest national monuments.Bond told the Huffington Post that he felt “scared,” “angry,” and “sad for our country…I want to make sure that our national monuments are available for my kids and for future generations.”Bond plans to tour 27 natural sites this summer, including Bears’ Ears, whose threatened status and celebrity attention NPQ reported earlier this year. He has a sponsorship from Patagonia, the outdoor apparel company that has donated tens of millions of dollars in cash, in-kind, and work hours to environmental nonprofits.NPQ noted back in January that Ryan Zinke, President Donald Trump’s Secretary of the Interior, “received an extremely low lifetime score of three percent regarding his environmental record from the League of Conservation Voters.”The 27 sites Bond plans to visit this summer are not a random number; they’re 27 sites that were part of Trump’s recent executive order, the “Review of Designations Under the Antiquities Act.”The concern stated in the review is,Monument designations that result from a lack of public outreach and proper coordination with State, tribal, and local officials and other relevant stakeholders may also create barriers to achieving energy independence, restrict public access to and use of Federal lands, burden State, tribal, and local governments, and otherwise curtail economic growth.Zinke is ordered to determine whether “the designation or expansion was made without adequate public outreach and coordination with relevant stakeholders, to determine whether each designation or expansion conforms to the policy set forth in section 1 of this order.”Of course, failure to coordinate properly with tribal officials has been the source of plenty of trouble for the Trump administration, from the Bears’ Ears backlash to the protests at Standing Rock, but it’s not restricted economic growth that caused the controversy.Nine-year-old Bond may not understand the complicated history of tribal relations to government-owned land or the pressure for energy independence, but he knows one thing: The environment has to be protected if he wants to tour sites like Giant Sequoia or Craters of the Moon when he’s older. Bond plans to enlist more fourth-graders in his effort; we hope there are more kids like him.—Erin RubinShare67Tweet15Share11Email93 Shares